12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

OX51: Phase II started

Orexo began a double-blind, placebo-controlled, European Phase II trial to evaluate 3 escalating doses of oral OX51 in about 200...

Read the full 78 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >